Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.
Butyrophilins
/ genetics
Cell Communication
Cell Line, Tumor
Dendritic Cells
/ immunology
Humans
Immunotherapy
Infections
/ immunology
Interferon Type I
/ metabolism
Interferon-gamma
/ metabolism
Neoplasms
/ immunology
Receptors, Antigen, T-Cell, gamma-delta
/ metabolism
Signal Transduction
T-Lymphocytes
/ immunology
Zoledronic Acid
BTN3A
cross-talk
immune checkpoint
pDCs
γδ T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
01
2020
accepted:
15
04
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
6
5
2021
Statut:
epublish
Résumé
Plasmacytoid DCs (pDCs) and γδT cells are both critical players in immunosurveillance against pathogens and cancer due to their ability to sense microbes and cell stress through recognition of pathogen-associated molecular patterns or altered metabolism [phosphoantigens (PAgs)]. Their unique features, high functional plasticity and ability to interact with many immune cell types allow them to bridge innate and adaptive immunity, initiating and orientating widely immune responses, hence contributing to protective and pathogenic immune responses. Yet, despite strategic and closed missions, potential interactions between pDCs and γδT cells are still unknown. Here we investigated whether there is interplay between pDCs and γδT cells and the underlying molecular mechanisms. Purified human pDCs and γδT cells were cocultured in presence of TLR-L, PAg, and zoledronate (Zol) to mimic both infectious and tumor settings. We demonstrated that TLR7/9L- or Zol-stimulated pDCs drive potent γδT-cell activation, Th1 cytokine secretion and cytotoxic activity. Conversely PAg-activated γδT cells trigger pDC phenotypic changes and functional activities. We provided evidence that pDCs and γδT cells cross-regulate each other through soluble factors and cell-cell contacts, especially type I/II IFNs and BTN3A. Such interplay could be modulated by blocking selective immune checkpoints. Our study highlighted crucial bidirectional interactions between these key potent immune players. The exploitation of pDC-γδT cells interplay represents a promising opportunity to design novel immunotherapeutic strategies and restore appropriate immune responses in cancers, infections and autoimmune diseases.
Identifiants
pubmed: 32435249
doi: 10.3389/fimmu.2020.00861
pmc: PMC7218166
doi:
Substances chimiques
BTNL9 protein, human
0
Butyrophilins
0
Interferon Type I
0
Receptors, Antigen, T-Cell, gamma-delta
0
Zoledronic Acid
6XC1PAD3KF
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
861Informations de copyright
Copyright © 2020 Girard, Ponsard, Charles, Chaperot and Aspord.
Références
J Exp Med. 2002 Dec 16;196(12):1575-84
pubmed: 12486100
J Immunol. 2009 Jun 1;182(11):6815-23
pubmed: 19454677
PLoS One. 2014 Oct 23;9(10):e111095
pubmed: 25340508
Oncoimmunology. 2015 Apr 1;4(8):e1021538
pubmed: 26405575
Nat Rev Cancer. 2019 Jul;19(7):392-404
pubmed: 31209264
Clin Immunol. 2002 Jun;103(3 Pt 1):296-302
pubmed: 12173304
J Immunol. 2009 Sep 15;183(6):3625-33
pubmed: 19710464
Nat Rev Immunol. 2013 Feb;13(2):88-100
pubmed: 23348415
J Immunol. 2015 Mar 1;194(5):2390-8
pubmed: 25637025
Front Biosci. 2008 May 01;13:6872-85
pubmed: 18508701
Scand J Immunol. 2007 Aug-Sep;66(2-3):320-8
pubmed: 17635809
Ann N Y Acad Sci. 2010 Jan;1183:89-103
pubmed: 20146710
J Exp Med. 2003 Jan 20;197(2):163-8
pubmed: 12538656
Front Immunol. 2015 Jan 22;5:688
pubmed: 25657647
Oncoimmunology. 2017 Jan 6;6(3):e1278099
pubmed: 28405500
Nat Immunol. 2004 Dec;5(12):1219-26
pubmed: 15549123
Cancer Res. 2013 Feb 1;73(3):1063-75
pubmed: 23345163
Nat Rev Immunol. 2008 Aug;8(8):594-606
pubmed: 18641647
J Immunol. 2019 Jul 15;203(2):311-320
pubmed: 31285310
J Clin Invest. 2005 Mar;115(3):739-46
pubmed: 15696196
Nat Rev Immunol. 2012 Mar 22;12(4):239-52
pubmed: 22437937
Cancer Immunol Immunother. 2012 Aug;61(8):1279-88
pubmed: 22294456
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
Immunology. 2004 Jul;112(3):369-77
pubmed: 15196204
J Immunol. 2006 Jan 1;176(1):248-55
pubmed: 16365416
J Immunol. 2005 Aug 15;175(4):2144-51
pubmed: 16081780
Cancer Immunol Immunother. 2010 Nov;59(11):1611-9
pubmed: 20582413
Immunity. 2008 Sep 19;29(3):352-61
pubmed: 18799143
Oncotarget. 2016 Sep 20;7(38):60896-60905
pubmed: 27590513
J Immunol. 2006 Feb 1;176(3):1386-93
pubmed: 16424165
Oncoimmunology. 2013 Sep 1;2(9):e25636
pubmed: 24319636
Immunity. 2014 Apr 17;40(4):490-500
pubmed: 24703779
Cancer Res. 2012 Oct 15;72(20):5188-97
pubmed: 22836755
Immunol Lett. 2005 Jun 15;99(1):103-8
pubmed: 15894118
Oncoimmunology. 2014 Jan 1;3(1):e27560
pubmed: 24719793
Blood. 2007 Aug 1;110(3):921-7
pubmed: 17403919
Front Immunol. 2014 Dec 08;5:622
pubmed: 25538706
Trends Immunol. 2012 May;33(5):199-206
pubmed: 22364810
Front Immunol. 2018 Apr 20;9:828
pubmed: 29731756
Front Immunol. 2014 Dec 19;5:648
pubmed: 25566259
Immunity. 2001 Jul;15(1):83-93
pubmed: 11485740
Front Immunol. 2018 Jul 11;9:1601
pubmed: 30050536
J Immunol. 2007 Sep 1;179(5):3057-64
pubmed: 17709520
J Exp Med. 2003 Aug 4;198(3):391-7
pubmed: 12900516
J Immunol. 2003 Feb 1;170(3):1249-56
pubmed: 12538683
Trends Immunol. 2016 Oct;37(10):690-702
pubmed: 27567182
Front Immunol. 2017 Feb 09;8:105
pubmed: 28232834
Immunity. 2019 Apr 16;50(4):1043-1053.e5
pubmed: 30902636
Nat Immunol. 2013 Sep;14(9):908-16
pubmed: 23872678
Front Immunol. 2015 Jan 05;5:657
pubmed: 25601861
Trends Cancer. 2017 Aug;3(8):561-570
pubmed: 28780933
Front Immunol. 2017 Jun 30;8:761
pubmed: 28713381
Nat Rev Immunol. 2010 Jul;10(7):467-78
pubmed: 20539306
Infect Immun. 2008 Jan;76(1):426-36
pubmed: 17923514
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1039-1044
pubmed: 29339503
J Immunol. 2005 Jan 1;174(1):252-60
pubmed: 15611247
Immunity. 2019 Jan 15;50(1):37-50
pubmed: 30650380
Cancer Immunol Immunother. 2010 Jul;59(7):1109-20
pubmed: 20306041
Oncoimmunology. 2014 Jan 1;3(1):e27402
pubmed: 24701375
Front Immunol. 2018 Apr 04;9:662
pubmed: 29670629
Eur J Cancer. 2016 Jan;53:125-34
pubmed: 26707829
J Invest Dermatol. 2012 Oct;132(10):2395-2406
pubmed: 22696054
Eur J Immunol. 2003 Apr;33(4):1052-62
pubmed: 12672071
FEMS Immunol Med Microbiol. 2010 Jun 1;59(1):71-80
pubmed: 20337718
Nat Commun. 2017 Jun 05;8:15663
pubmed: 28580927
Pharmaceuticals (Basel). 2015 Feb 12;8(1):40-61
pubmed: 25686210